NCT00001123View on ClinicalTrials.gov

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

NACompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

Not specified

Study Completion Date

November 30, 2005

Conditions

Hantavirus Pulmonary Syndrome

Interventions

DRUG

Ribavirin

Trial Locations (1)

35294

NIAID/DMID/CASG Central Unit, Birmingham

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH